Randomized Phase 1/2 Evaluation of Neoadjuvant Administration of a Chemokine-Modulatory Regimen in Patients With Recurrent Resectable Colorectal Cancer

Trial Profile

Randomized Phase 1/2 Evaluation of Neoadjuvant Administration of a Chemokine-Modulatory Regimen in Patients With Recurrent Resectable Colorectal Cancer

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 30 Jan 2018

At a glance

  • Drugs Rintatolimod (Primary) ; Celecoxib; Interferon alpha-2b
  • Indications Colorectal cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 24 Jan 2018 Status changed from recruiting to discontinued.
    • 10 Jun 2017 Biomarkers information updated
    • 02 Feb 2017 Planned End Date changed from 1 Aug 2017 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top